Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

NCT03629171 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine
DRUG: Venetoclax

Sponsor

M.D. Anderson Cancer Center